Cargando…
Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report
Glioblastoma (GBM) is the most common malignant brain tumor. Less than 1% of patients survive longer than 10 years. A 77-year-old woman was diagnosed with MGMT-methylated GBM in 2009. The patient received cilengitide as part of the CENTRIC clinical trial in conjunction with standard radiation and ch...
Autores principales: | Alalami, Huda, Bannykh, Serguei, Fan, Xuemo, Hu, Jethro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171035/ https://www.ncbi.nlm.nih.gov/pubmed/37092563 http://dx.doi.org/10.2217/cns-2022-0017 |
Ejemplares similares
-
Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS
por: Liu, Andy, et al.
Publicado: (2023) -
Clinical response to pazopanib in a patient with endolymphatic sac tumor not associated with von Hippel-Lindau syndrome
por: Nelson, Thomas, et al.
Publicado: (2020) -
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
por: Weller, Michael, et al.
Publicado: (2016) -
Adult Brainstem Glioblastoma Multiforme: Long-term Survivor
por: Barnard, Zachary R, et al.
Publicado: (2015) -
Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era
por: Carico, Christine, et al.
Publicado: (2012)